Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that ...

Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a ...

A cardiovascular specialty hospital in north Texas decreased time to diagnosis for patients with cardiogenic shock by more than half, according to a study published in Critical Care Nurse.

Cardiogenic shock (CS) is a life-threatening condition leading to poor prognosis and high morbidity. The related inadequate cardiac output carries to tissue hypoperfusion, hypoxia and multi-organ ...

Most of the change in stage of cardiogenic shock (CS) occurred within the first 24 hours of presentation, with little change thereafter, according to a study by the Cardiogenic Shock Working Group ...

In this paper, we introduce a data processing pipeline for cardiogenic shock (CS) prediction from the MIMIC III database of intensive cardiac care unit patients with acute coronary syndrome. The ...

Hospitals with lower risk-adjusted in-hospital mortality rates (RAMR) among patients with cardiogenic shock following acute myocardial infarction (AMI) demonstrated higher rates of revascularization ...

Danvers: Johnson & Johnson MedTech, has announced that the U.S. Food and Drug Administration (FDA) has expanded the ...

In light of recent advances in myocarditis care and the lack of a dedicated practice guideline, the document, published online this week in the ... starting with recognition of the three classic ...

In this randomized controlled trial, in older adults with non-ST-segment elevation myocardial infarction (NSTEMI), invasive ...